High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) - PubMed (original) (raw)
. 2008 Oct 1;112(7):2703-8.
doi: 10.1182/blood-2008-02-142422. Epub 2008 Jun 6.
Affiliations
- PMID: 18539899
- DOI: 10.1182/blood-2008-02-142422
Free article
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)
Cihan Ay et al. Blood. 2008.
Free article
Abstract
Cancer patients are at high risk for venous thromboembolism (VTE). Laboratory parameters with a predictive value for VTE could help stratify patients into high- or low-risk groups. The cell adhesion molecule P-selectin was recently identified as risk factor for VTE. To investigate soluble P-selectin (sP-selectin) in cancer patients as risk predictor for VTE, we performed a prospective cohort study of 687 cancer patients and followed them for a median (IQR) of 415 (221-722) days. Main tumor entities were malignancies of the breast (n = 125), lung (n = 86), gastrointestinal tract (n = 130), pancreas (n = 42), kidney (n = 19), prostate (n = 72), and brain (n = 80); 91 had hematologic malignancies; 42 had other tumors. VTE occurred in 44 (6.4%) patients. In multivariable analysis, elevated sP-selectin (cutoff level, 53.1 ng/mL, 75th percentile of study population) was a statistically significant risk factor for VTE after adjustment for age, sex, surgery, chemotherapy, and radiotherapy (hazard ratio = 2.6, 95% confidence interval, 1.4-4.9, P = .003). The cumulative probability of VTE after 6 months was 11.9% in patients with sP-selectin above and 3.7% in those below the 75th percentile (P = .002). High sP-selectin plasma levels independently predict VTE in cancer patients. Measurement of sP-selectin at diagnosis of cancer could help identify patients at increased risk for VTE.
Comment in
- Cancer and thrombosis is a sticky business.
Rickles FR. Rickles FR. Blood. 2008 Oct 1;112(7):2594-5. doi: 10.1182/blood-2008-07-165647. Blood. 2008. PMID: 18809764 No abstract available. - P-selectin ready for prime time?
Rana P, Julian J, Levine M. Rana P, et al. Blood. 2009 Feb 19;113(8):1860; author reply 1860-1. doi: 10.1182/blood-2008-10-185652. Blood. 2009. PMID: 19228932 No abstract available.
Similar articles
- High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).
Simanek R, Vormittag R, Ay C, Alguel G, Dunkler D, Schwarzinger I, Steger G, Jaeger U, Zielinski C, Pabinger I. Simanek R, et al. J Thromb Haemost. 2010 Jan;8(1):114-20. doi: 10.1111/j.1538-7836.2009.03680.x. Epub 2009 Nov 2. J Thromb Haemost. 2010. PMID: 19889150 - D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, Quehenberger P, Wagner O, Zielinski C, Pabinger I. Ay C, et al. J Clin Oncol. 2009 Sep 1;27(25):4124-9. doi: 10.1200/JCO.2008.21.7752. Epub 2009 Jul 27. J Clin Oncol. 2009. PMID: 19636003 - Thrombosis risk and survival in cancer patients with elevated C-reactive protein.
Kanz R, Vukovich T, Vormittag R, Dunkler D, Ay C, Thaler J, Haselböck J, Scheithauer W, Zielinski C, Pabinger I. Kanz R, et al. J Thromb Haemost. 2011 Jan;9(1):57-63. doi: 10.1111/j.1538-7836.2010.04069.x. J Thromb Haemost. 2011. PMID: 20874781 - Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS).
Königsbrügge O, Pabinger I, Ay C. Königsbrügge O, et al. Thromb Res. 2014 May;133 Suppl 2:S39-43. doi: 10.1016/S0049-3848(14)50007-2. Thromb Res. 2014. PMID: 24862144 Review. - The role of soluble P selectin in the diagnosis of venous thromboembolism.
Antonopoulos CN, Sfyroeras GS, Kakisis JD, Moulakakis KG, Liapis CD. Antonopoulos CN, et al. Thromb Res. 2014 Jan;133(1):17-24. doi: 10.1016/j.thromres.2013.08.014. Epub 2013 Aug 23. Thromb Res. 2014. PMID: 24012101 Review.
Cited by
- Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States.
Khorana AA, Dalal MR, Lin J, Connolly GC. Khorana AA, et al. Clinicoecon Outcomes Res. 2013;5:101-8. doi: 10.2147/CEOR.S39964. Epub 2013 Feb 13. Clinicoecon Outcomes Res. 2013. PMID: 23430767 Free PMC article. - Inflammation, Infection and Venous Thromboembolism.
Colling ME, Tourdot BE, Kanthi Y. Colling ME, et al. Circ Res. 2021 Jun 11;128(12):2017-2036. doi: 10.1161/CIRCRESAHA.121.318225. Epub 2021 Jun 10. Circ Res. 2021. PMID: 34110909 Free PMC article. Review. - Thrombosis and cancer.
Young A, Chapman O, Connor C, Poole C, Rose P, Kakkar AK. Young A, et al. Nat Rev Clin Oncol. 2012 Jul 10;9(8):437-49. doi: 10.1038/nrclinonc.2012.106. Nat Rev Clin Oncol. 2012. PMID: 22777060 Review. - Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer.
Moik F, Posch F, Grilz E, Scheithauer W, Pabinger I, Prager G, Ay C. Moik F, et al. Thromb Res. 2020 Mar;187:9-17. doi: 10.1016/j.thromres.2020.01.002. Epub 2020 Jan 7. Thromb Res. 2020. PMID: 31945589 Free PMC article. - Advances in the Diagnosis of Venous Thromboembolism: A Literature Review.
Patel H, Sun H, Hussain AN, Vakde T. Patel H, et al. Diagnostics (Basel). 2020 Jun 2;10(6):365. doi: 10.3390/diagnostics10060365. Diagnostics (Basel). 2020. PMID: 32498355 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous